Back to Sectors

SHPH

Shuttle Pharmaceuticals Holdings, Inc.
4 filings tracked
healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

BEARISH | 90% | 3/31/2026 | margin compressionBULLISH | 70% | 3/31/2026 | acquisitionNEUTRAL | 60% | 3/31/2026 | capital raiseNEUTRAL | 40% | 3/31/2026 | management changeBULLISH | 70% | 5/15/2026 | margin expansionNEUTRAL | 50% | 5/15/2026 | capital raiseBULLISH | 80% | 5/15/2026 | acquisitionBEARISH | 90% | 5/15/2026 | dilution riskBULLISH | 70% | 5/15/2026 | margin expansionNEUTRAL | 50% | 5/15/2026 | capital raiseBULLISH | 80% | 5/15/2026 | acquisitionBEARISH | 90% | 5/15/2026 | dilution riskNEUTRAL | 60% | 5/27/2026 | capital raiseNEUTRAL | 30% | 5/27/2026 | management changeMar 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

neutralMay 27

Authorization of reverse stock split to maintain listing and facilitate future capital access.

capital raise
60%
neutralMay 27

Re-election of four directors to the board.

management change
30%
bullishMay 15

R&D expenses collapsed by 83% following the wind-down of clinical trials.

margin expansion
70%
neutralMay 15

Raised $3.2 million in net proceeds from a March 2026 public offering.

capital raise
50%
bullishMay 15

Acquired Molecule.ai to pivot toward an AI-driven drug discovery platform.

acquisition
80%
bearishMay 15

Heavy reliance on pre-funded warrants and public offerings to maintain Nasdaq compliance and operations.

dilution risk
90%
bullishMay 15

R&D expenses collapsed by 83% following the wind-down of clinical trials.

margin expansion
70%
neutralMay 15

Raised $3.2 million in net proceeds from a March 2026 public offering.

capital raise
50%
bullishMay 15

Acquired Molecule.ai to pivot toward an AI-driven drug discovery platform.

acquisition
80%
bearishMay 15

Heavy reliance on pre-funded warrants and public offerings to maintain Nasdaq compliance and operations.

dilution risk
90%
bearishMar 31

Zero revenue generated against $11.7 million net loss.

margin compression
90%
bullishMar 31

Acquisition of Molecule.ai AI platform to pivot business model.

acquisition
70%
neutralMar 31

Multiple dilutive equity raises to maintain Nasdaq listing and fund operations.

capital raise
60%
neutralMar 31

Resignation of multiple board members and CFO during the transition period.

management change
40%

Filing History

8-KMay 27, 2026

The 2026 Annual Meeting results for Shuttle Pharmaceuticals center on a pivotal vote to authorize a reverse stock split, a move that is both a defensive necessity and a potential risk. While the approval ensures the company can maintain its Nasdaq listing, the breadth of the authorized split ratio introduces significant uncertainty regarding future share price and liquidity. Investors must now weigh the benefit of a stabilized listing against the risk that management is using this tool to hide deeper fundamental weaknesses in the company's cash runway. The outcome shifts the focus from corporate governance to the timing and magnitude of the actual split execution.

10-QMay 15, 2026

The Q1 2026 filing reveals a company at a crossroads, attempting to trade the binary risk of clinical trials for the execution risk of a software-as-a-service platform. While the collapse in R&D spending proves management's commitment to the pivot, the surge in general and administrative expenses and heavy marketing spend highlight the costs of rebranding and restructuring. The company has successfully regained Nasdaq compliance through equity raises, but the resulting dilution and the persistent working capital deficit leave little room for error. Ultimately, the investment thesis now hinges entirely on the commercial viability of Molecule.ai. If Shuttle can convert its technical milestones into paying B2B customers, the pivot will be viewed as a masterstroke of de-risking. However, the immediate reality is a cash-starved balance sheet and a total dependence on the capital markets to fund the gap between its current burn and its first dollar of revenue.

10-KMar 31, 2026

The 10-K filing for Shuttle Pharmaceuticals depicts a company at a critical crossroads, attempting to trade the binary risk of clinical trials for the scalable potential of AI software. The acquisition of Molecule.ai provides a tangible technological asset, but the financial statements reveal a fragile foundation. The company is currently operating as a pre-revenue entity that relies entirely on capital markets to fund its existence, evidenced by the frequent issuance of pre-funded warrants and common stock. Ultimately, the investment thesis hinges on the speed of commercialization. If Shuttle can successfully convert the Molecule.ai platform into a series of high-margin licensing agreements, it could justify its current valuation and stabilize its balance sheet. However, the combination of a working capital deficit, ineffective internal controls, and a history of reverse splits suggests that the margin for error is non-existent. Investors are essentially betting on a complete business model pivot while the company struggles with basic financial solvency.